Biotech Values

[DewDiligence]

Reuters chimes in on Xeljanz approval—price is ~$25K*/year:

http://www.reuters.com/article/2012/11/06/pfizer-arthritis-idUSL1E8M6D8820121106

Note: The FDA approved only the 5mg dose, not the 10mg dose that was also tested in phase-3 trials. However, the non-approval of the 10mg dose is (IMO) less consequential than the broadness of the second-line label (i.e. no requirement for prior treatment with a TNF-alpha drug).

*This was subsequently confirmed by PFE.